<DOC>
	<DOCNO>NCT03075228</DOCNO>
	<brief_summary>Rationale : The microbial composition small intestine ( SI ) differs largely composition feces . Many physiological process related health , immunoregulation metabolic programming , mainly take place SI . Therefore , SI , microbiota perspective , relevant large intestine . There indication microbiota composition different lean obese subject , related insulin resistance . However , indication mainly base analysis fecal sample . Therefore , analysis microbiota composition proximal part gastrointestinal ( GI ) tract may provide new insight microbial specie involve related metabolic homeostasis location . The IntelliCapÂ® CR system offer minimally invasive tool able collect reliable sample SI , show NIZO clinical validation study . The main aim current study explore compare upper GI microbiota composition lean obese subject , order generate new lead development product may target upper GI microbiota community specific specie thereof , may impact maintenance metabolic homeostasis . This may provide new opportunity treatment , reduction prevention overweight and/or obesity insulin resistance .</brief_summary>
	<brief_title>Comparison Microbial Composition Lean Obese Subjects</brief_title>
	<detailed_description />
	<criteria>Female ; Age : 2550y ; Lean : BMI 1923 kg/m2 , waist circumference &lt; 80 cm , fast glucose &lt; 6.1 mmol/L ; Obese : BMI 3035 kg/m2 , waist circumference &gt; 88 cm , fast glucose &gt; =6.1 &lt; 7.5 mmol/L ; Healthy assess NIZO lifestyle health questionnaire ( `` Verklaring leefgewoonten en gezondheid '' ) ; Healthy assess result prestudy safety laboratory test ( clinical chemistry : liver/kidney function etc ) ; Regular normal Dutch eating habit assess NIZO lifestyle health questionnaire ( 3 main meal per day ) ; Regular bowel movement ( defecation average day , least 4 times/week ) . Participation clinical trial oral , intravenous inhalatory administration substance 90 day study start ; History presence clinically important disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study : type 1 type 2 diabetes ; gastrointestinal disease ; bariatric surgery ; cardiovascular disease , liver renal failure disease thyroid gland , cancer ; infectious disease , history chronic active inflammatory disorder food allergy ; Use antibiotics one ( 1 ) year prior study start ; # Constipation/infrequent bowel movement ( defecation &lt; 4 time per week ) ; Having diarrhea within 3 month prior study start ( least 3 loose stool per day ) ; Use laxatives , fiber supplement ( e.g . lactulose , inulin ) , glucose lower drug , insulin , antiobesity drug , immunosuppressive drug ( e.g . systemic corticosteroid , cyclosporine , azathioprine , antibody ) three ( 3 ) month prior study start ; Use temporary irregular medication diabetes , dyslipidemia hypertension ; Use prescribe nonprescribed medication ( paracetamol ) include antacid , H2 receptor antagonist , proton pump inhibitor , analgesic , herbal remedy antiinflammatory drug ( e.g . NSAIDs ) three ( 3 ) week prior study start ; Use probiotic prebiotics three ( 3 ) month prior study start ; Mental status incompatible proper conduct study ; Presence swallow passage disorder ; Carrying pacemaker ( implant ) medical electronic device ; Scheduled MRI scan study period ; Not willing Xray capsule recover faeces ; Alcohol consumption &gt; 15 units/week &gt; 3/day . In case le alcohol consumption : willing stop study ; Drug abuse , willing/able stop study ; Heavy exercise sport train &gt; 10 hours/week ; Smoking ; Active recent participation weight loss program include weight change ( increase loss ) &gt; 3 kg last three ( 3 ) month ; Reported unexplained weight loss weight gain &gt; 5 kg year prior prestudy screen ; Reported slimming medically prescribe diet ; Reported special diet ; Pregnant planning become pregnant study , breastfeed ; Postmenopausal woman unstable hormone replacement therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>microbiota</keyword>
	<keyword>small intestine</keyword>
	<keyword>metabolic disease</keyword>
</DOC>